Praxis Precision Medicines Reports Q3 Non-GAAP EPS Beat
Praxis Precision Medicines (PRAX) reported third-quarter non-GAAP earnings per share of -$3.23, surpassing analyst expectations by $0.40. The results indicate a stronger-than-anticipated financial performance relative to consensus estimates for the period. The company also demonstrated significant liquidity growth during the quarter. As of September 30, 2026, Praxis held $1.3 billion in cash, cash equivalents, and marketable securities, representing an increase of approximately $374 million from its December 31, 2025, position.
Tickers: $PRAX